Agreement Focuses on Development of Clinical Specimen Repositories, Laboratory Services, and Research.
MRIGlobal and the University of Maryland School of Medicine today announced an intention to collaborate in the development of clinical specimen repositories, laboratory services for clinical trials, and research opportunities. The work will be performed under the collaboration agreement by MRIGlobal Dx, a division of MRIGlobal.
The non-exclusive memo of understanding has an initial two-year term, with annual renewals ongoing. Other terms of the agreement were not released.
With the agreement, the University of Maryland School of Medicine and MRIGlobal Dx plan to explore opportunities for procurement of clinical samples and patient specimen collection and banking.
Researchers in molecular and translational medicine use specimen repositories to develop new ways to diagnose, prevent, or treat diseases. Specimens may include fluids, tissues, tumors, cells and genetic material.
"This is a powerful agreement between two organizations committed to excellence and advancing knowledge," said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal. "We are delighted to collaborate with the University of Maryland School of Medicine in bringing new diagnostic products and therapeutics to market."
University of Maryland School of Medicine Dean E. Albert Reece, who is Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor at the School of Medicine, commented: "As we continue to develop our resources as a top biomedical research institution, this agreement provides a critical service for our laboratories and clinical trials.
"We are excited to partner with a leading firm like MRIGlobal in this endeavor," he said.
For more information, visit www.mriglobaldx.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.